Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

• click to rate

  Posted by Two Blokes April 23, 2025 - Filed in Stock - 19 views
  
  The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043